Preoperative and postoperative chemotherapy for biliary tract cancers and chemotherapy for unresected advanced biliary tract cancers

DOI
  • Ueki Toshiharu
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Ihara Ryo
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Doi Masamune
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Maruo Touru
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Nagayama Rintaro
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Hatayama Katsuko
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Hiratsuka Hiroaki
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Tanaka Toshiyuki
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Noma Eijiro
    Department of Gastroenterology, Fukuoka University Chikushi Hospital
  • Mitsuyasu Tomoko
    Department of Gastroenterology, Fukuoka University Chikushi Hospital

Bibliographic Information

Other Title
  • 胆道癌化学療法―術前・術後・非切除―

Search this article

Description

<p>Surgical resection is the only radical treatment for bile duct cancer. However, it is often discovered in an advanced and unresectable state, either because it is advanced cancer at the time of diagnosis or because of extensive invasion or distant metastasis. Chemotherapy is performed after resection or in unresectable cases. In Japan, the standard first-line therapy for unresectable bile duct cancer is combination therapy with gemcitabine plus cisplatin. S-1 is often used as second-line therapy, but evidence for it has not been established, including in an adjuvant chemotherapy for bile duct cancer. Chemotherapy in resectable cases and conversion therapy in unresectable cases is sought through trial and error. The results of currently ongoing prospective trials are awaited. Advances in biomarkers to predict the outcome following chemotherapy and in personalized medicine are also anticipated.</p>

Journal

  • Tando

    Tando 32 (2), 209-215, 2018-05-31

    Japan Biliary Association

Keywords

Details 詳細情報について

Report a problem

Back to top